|
US2019358349A1
|
|
Methods for evaluation of treatment and progression of neurological disorders
|
|
WO2019152432A1
|
|
Crispr knock-out of the alpha-synuclein triplication model of parkinson's disease
|
|
WO2019152433A1
|
|
Crispr-based downregulation of alpha-synuclein expression as a novel parkinson's disease therapeutic
|
|
US2018179594A1
|
|
Multiple system atrophy and the treatment thereof
|
|
US2018110768A1
|
|
Methods and compositions for reduction of side effects of therapeutic treatments
|
|
US2019085394A1
|
|
Refining diagnosis and treatment of complex multi-symptom neurological disorders
|
|
AU2011203482A1
|
|
Methods and compositions for reduction of side effects of therapeutic treatments
|
|
WO2010008486A2
|
|
Pluripotent cell lines and methods of use thereof
|
